Spots Global Cancer Trial Database for Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Study Description

Brief Summary: RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects of giving sunitinib malate and to see how well it works in treating patients with locally recurrent, locally advanced, unresectable, or metastatic urinary tract cancer.

Detailed Description: OBJECTIVES: Primary * To determine the time to disease progression (defined as the time from diagnosis of metastatic urothelial carcinoma until first confirmed progression of the disease) in patients with locally recurrent, locally advanced, unresectable, or metastatic urothelial cancer treated with sunitinib malate and ineligible for cisplatin-based chemotherapy. * To determine the safety of this drug in these patients. Secondary * To determine the progression-free survival of patients treated with this drug. * To determine the overall response rate in patients treated with this drug. * To determine the overall survival of patients treated with this drug. * To determine the time to treatment failure in patients treated with this drug. * To determine the pharmacodynamic profile of this drug in pre- and post-treatment serum and tumor tissue (i.e., IL8, VEGF, MMP9, bFGF, p27, Ki-67, and apoptosis \[H/E\]) at week 6, and if possible, at time of progression. * To determine the quality of life of patients treated with this drug using the QLQ-C30 version 3 questionnaire. OUTLINE: This is a multicenter study. Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients complete quality-of-life questionnaire (EORTC QLQ-C30) before, during, and at the end of study treatment. Serum and tumor tissue samples are collected at baseline and after study treatment for pharmacodynamic studies. Samples are analyzed for markers (i.e., IL8, VEGF, MMP9, bFGF, p27, Ki-67, and apoptosis \[H/E\]) via immunohistochemistry. After completion of study treatment, patients are followed for 28 days and then every 2 months for up to 3 years.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial